{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:42:27Z","timestamp":1776300147406,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.09.007","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:25:00Z","timestamp":1664652300000},"page":"6455-6462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["\u2018Mix and Match\u2019 vaccination: Is dengue next?"],"prefix":"10.1016","volume":"40","author":[{"given":"Camila D.","family":"Odio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah C.","family":"Katzelnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.007_b0005","doi-asserted-by":"crossref","first-page":"100712","DOI":"10.1016\/j.eclinm.2020.100712","article-title":"Global, regional, and national dengue burden from 1990 to 2017: a systematic analysis based on the global burden of disease study 2017","volume":"32","author":"Zeng","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coviro.2020.09.004","article-title":"Dengue vaccine development by the year 2020: challenges and prospects","volume":"43","author":"Wilder-Smith","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/cid\/ciab288","article-title":"Analysis of hospitalized and severe dengue cases over the 6 years of follow-up of the tetravalent dengue vaccine (CYD-TDV) efficacy trials in Asia and Latin America","volume":"73","author":"Forrat","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","article-title":"Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination","volume":"225","author":"Lopez-Medina","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/ciab864","article-title":"Three-year efficacy and safety of Takeda\u2019s dengue vaccine candidate (TAK-003)","volume":"75","author":"Rivera","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy Flavivirus-Naive Adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005584","article-title":"In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination","volume":"11","author":"Whitehead","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0050","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.immuni.2019.06.024","article-title":"Activation Dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin","volume":"51","author":"Andrews","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2022.09.007_b0065","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0070","series-title":"Overview of EU\/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making","year":"2021"},{"key":"10.1016\/j.vaccine.2022.09.007_b0075","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/ciab705","article-title":"Heterologous ChAdOx1-S\/BNT162b2 vaccination: neutralizing antibody response to SARS-CoV-2","volume":"74","author":"Dimeglio","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0080","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0085","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S1473-3099(21)00420-5","article-title":"Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"21","author":"Tenbusch","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous ChadOx1\/BNT162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.09.007_b0095","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0100","doi-asserted-by":"crossref","first-page":"100249","DOI":"10.1016\/j.lanepe.2021.100249","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2022.09.007_b0105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.09.007_b0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.09.007_b0115","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.09.007_b0120","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0125","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0130","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3018(18)30071-7","article-title":"Subtype C ALVAC-HIV and bivalent subtype C gp120\/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1\/2 trial","volume":"5","author":"Bekker","year":"2018","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.09.007_b0135","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3018(19)30262-0","article-title":"Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial","volume":"6","author":"Pantaleo","year":"2019","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.vaccine.2022.09.007_b0140","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1172\/JCI75894","article-title":"HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial","volume":"124","author":"Bart","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.vaccine.2022.09.007_b0145","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.3389\/fimmu.2019.02941","article-title":"Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses","volume":"10","author":"Perdiguero","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0155","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.09.007_b0160","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jit273","article-title":"Reduced risk of disease during postsecondary dengue virus infections","volume":"208","author":"Olkowski","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0165","doi-asserted-by":"crossref","first-page":"e147066","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2022.09.007_b0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.09.007_b0175","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/infdis\/140.4.527","article-title":"In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody","volume":"140","author":"Halstead","year":"1979","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature14130","article-title":"Recognition determinants of broadly neutralizing human antibodies against dengue viruses","volume":"520","author":"Rouvinski","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.09.007_b0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/infdis\/jiq059","article-title":"Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic","volume":"203","author":"Durbin","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0190","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1128\/JVI.00273-15","article-title":"Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies","volume":"89","author":"Tsai","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0195","doi-asserted-by":"crossref","first-page":"e52384","DOI":"10.7554\/eLife.52384","article-title":"Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics","volume":"8","author":"Durham","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.vaccine.2022.09.007_b0200","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-020-00216-0","article-title":"Sequential immunization induces strong and broad immunity against all four dengue virus serotypes","volume":"5","author":"Hou","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2022.09.007_b0205","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.cell.2015.01.027","article-title":"Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.09.007_b0210","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/j.vaccine.2015.09.008","article-title":"Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study","volume":"33","author":"Rupp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0215","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.vaccine.2013.08.088","article-title":"Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA","volume":"31","author":"Dayan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009258","article-title":"Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)","volume":"15","author":"White","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0225","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue-exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0230","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2019.01956","article-title":"Can complementary prime-boost immunization strategies be an alternative and promising vaccine approach against dengue virus?","volume":"10","author":"Vald\u00e9s","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0235","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4269\/ajtmh.2001.65.420","article-title":"Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine","volume":"65","author":"Simmons","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.09.007_b0240","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1128\/JVI.00284-06","article-title":"Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques","volume":"80","author":"Simmons","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0245","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/vim.2005.18.709","article-title":"DNA priming E and NS1 constructs\u2013homologous proteins boosting immunization strategy to improve immune response against dengue in mice","volume":"18","author":"Mellado-S\u00e1nchez","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0250","doi-asserted-by":"crossref","unstructured":"Mellado-S\u00e1nchez G, Garc\u00eda-Machorro J, Sandoval-Montes C, Guti\u00e9rrez-Casta\u00f1eda B, Rojo-Dom\u00ednguez A, Garc\u00eda-Cordero J, et al. A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model. Arch Virol. 2010;155:847-56.","DOI":"10.1007\/s00705-010-0652-x"},{"key":"10.1016\/j.vaccine.2022.09.007_b0255","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1128\/JVI.00996-07","article-title":"A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0260","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the E protein of dengue virus type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2022.09.007_b0265","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-month-interval dosing study in adults indicates that a single dose of the National Institute of Allergy and Infectious Diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0270","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4269\/ajtmh.20-0042","article-title":"Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a phase-i randomized clinical trial","volume":"103","author":"Durbin","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.09.007_b0275","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1099\/jgv.0.001271","article-title":"A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine","volume":"100","author":"Vald\u00e9s","year":"2019","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0280","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.09.007_b0285","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/infdis\/jiaa603","article-title":"Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial","volume":"223","author":"Lin","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0290","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2011.10-0436","article-title":"Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans","volume":"85","author":"Qiao","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.09.007_b0295","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.007_b0300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trivac.2015.03.002","article-title":"Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period","volume":"4","author":"Capeding","year":"2015","journal-title":"Trials in Vaccinology"},{"key":"10.1016\/j.vaccine.2022.09.007_b0305","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0310","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0315","doi-asserted-by":"crossref","first-page":"E2046","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.09.007_b0320","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2022.09.007_b0325","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1016\/j.vaccine.2020.05.088","article-title":"Combine dengue vaccines to optimize effectiveness","volume":"38","author":"Macias","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.007_b0330","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","article-title":"Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003","volume":"10","author":"Waickman","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.09.007_b0335","article-title":"12 COVID-19 Vaccination Strategies for Your Community","author":"Centers for Disease Control and Prevention.","year":"2021","journal-title":"Vaccines & Immunizations"},{"key":"10.1016\/j.vaccine.2022.09.007_b0340","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.1812055115","article-title":"Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies","volume":"116","author":"Raut","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.09.007_b0345","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/infdis\/jiab342","article-title":"Analysis of neutralizing antibodies as a correlate of instantaneous risk of hospitalized dengue in placebo recipients of dengue vaccine efficacy trials","volume":"225","author":"Huang","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0350","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.007_b0355","doi-asserted-by":"crossref","first-page":"eaaw9066","DOI":"10.1126\/scitranslmed.aaw9066","article-title":"Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality","volume":"12","author":"Maciejewski","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:18:37Z","timestamp":1759403917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2201101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":71,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X2201101X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u2018Mix and Match\u2019 vaccination: Is dengue next?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}